JS207
Sponsors
Fudan University, Shanghai Junshi Bioscience Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions
Advanced Colorectal CancerAdvanced Malignant Solid TumorsAdvanced Malignant TumorBreast CancerBreast NeoplasmBreast TumorsEarly-stage Breast CancerHER2-negative Breast Cancer
Phase 1
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
Active, not recruitingNCT06022250
Start: 2023-09-26End: 2026-06-30Updated: 2025-09-18
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors
RecruitingNCT06571422
Start: 2024-10-23End: 2027-04-30Target: 93Updated: 2025-02-21
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
RecruitingNCT07466160
Start: 2026-02-11End: 2029-12-31Target: 280Updated: 2026-03-12
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
RecruitingNCT05582499
Start: 2022-11-01End: 2028-09-30Target: 716Updated: 2025-08-22
A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer
RecruitingNCT06868836
Start: 2025-05-30End: 2027-04-30Target: 42Updated: 2025-06-27
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
RecruitingNCT06885385
Start: 2025-04-23End: 2027-02-13Target: 60Updated: 2025-06-24
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
Not yet recruitingNCT06944470
Start: 2025-04-20End: 2027-12-31Target: 76Updated: 2025-04-25
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
RecruitingNCT06954467
Start: 2025-05-29End: 2028-06-30Target: 72Updated: 2025-07-02
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
RecruitingNCT06969027
Start: 2025-06-19End: 2027-12-31Target: 84Updated: 2025-07-04